Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2006-10-01 (19 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: CERILLY (03350), Allier
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE NOUVELLE : revenue, balance sheet and financial ratios
PHARMACIE NOUVELLE is a French company
founded 19 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CERILLY (03350),
this company of category PME
shows in 2025 a net income positive of 79 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE NOUVELLE (SIREN 492094768)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
79 034 €
40 570 €
9 244 €
90 936 €
87 029 €
63 048 €
58 357 €
62 729 €
93 392 €
117 796 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE NOUVELLE generates positive net income of 79 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 118 k€ -> 79 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
79 034 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 82%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 50%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
82.487%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
50.35%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
11.023
4.708
2.968
1.927
0.914
0.35
1.806
0.48
100.279
82.487
Financial autonomy
83.018
86.377
88.404
91.744
91.023
90.186
90.802
90.69
46.438
50.35
Repayment capacity
None
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
82.492025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average+35 pts over 3 years
In 2025, the debt ratio of PHARMACIE NOUVELLE (82.49) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
50.35%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average-30 pts over 3 years
In 2025, the financial autonomy of PHARMACIE NOUVELLE (50.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 224.40. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
224.402
Liquidity indicators evolution PHARMACIE NOUVELLE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
250.036
204.26
222.212
275.756
237.826
234.601
301.987
224.924
245.286
224.402
Interest coverage
None
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
224.42025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good
In 2025, the liquidity ratio of PHARMACIE NOUVELLE (224.40) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of PHARMACIE NOUVELLE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE NOUVELLE is estimated at
1 255 464 €
(range 851 964€ - 1 969 996€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
851k€1255k€1969k€
1 255 464 €Range: 851 964€ - 1 969 996€
NAF 5 année 2025
Valuation method used
Net Income Multiple
79 034 €
×
15.9x
=1 255 464 €
Range: 851 964€ - 1 969 997€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE NOUVELLE with other companies in the same sector:
Frequently asked questions about PHARMACIE NOUVELLE
What is the revenue of PHARMACIE NOUVELLE ?
The revenue of PHARMACIE NOUVELLE is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE NOUVELLE profitable?
Yes, PHARMACIE NOUVELLE generated a net profit of 79 k€ in 2025.
Where is the headquarters of PHARMACIE NOUVELLE ?
The headquarters of PHARMACIE NOUVELLE is located in CERILLY (03350), in the department Allier.
Where to find the tax return of PHARMACIE NOUVELLE ?
The tax return of PHARMACIE NOUVELLE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE NOUVELLE operate?
PHARMACIE NOUVELLE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart